tyb
Karuna Therapeutics sold by PureTech Health LLC: $200.90m-Jan 22
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
PureTech Health plc, a biopharmaceutical company, focuses on developing medicines for dysfunctions of the Brain-Immune-Gut axis. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders, and cancer; microbiome-derived immune modulators for immune and infectious diseases; oral delivery approach of biologics, vaccines, and other drugs; platform to address androgenetic alopecia and aesthetic-related indications; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist program for the treatment of psychosis and cognition, including schizophrenia and Alzheimer's disease; monoclonal antibody-based therapeutics to treat pancreatic cancer and other solid tumors; and voice-based technology platform for monitoring and diagnosing psychological and physical medical conditions, such as depression, Alzheimer's disease, multiple sclerosis, and Parkinson's disease, as well as cardiovascular and respiratory diseases.
https://www.finviz.com/insidertrading.ashx?oc=1727395&tc=7&b=2
https://finance.yahoo.com/quote/ptchf/
RULER45 C-17A Globemaster wit transponder issue East of Kansas City
da truf